MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.860
+0.480
+14.20%
Closed 17:42 11/19 EST
OPEN
3.550
PREV CLOSE
3.380
HIGH
4.136
LOW
3.461
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
6.90
52 WEEK LOW
2.450
MARKET CAP
207.57M
P/E (TTM)
-1.8558
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CALA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CALA News

  • Benzinga's Top Upgrades, Downgrades For November 19, 2019
  • Benzinga.19h ago
  • Evercore downgrades bluebird bio and Clovis in premarket analyst action
  • Seeking Alpha - Article.21h ago
  • H.C. Wainwright Initiates Coverage On Calithera Biosciences with Buy Rating, Announces $7 Price Target
  • Benzinga.22h ago
  • Calithera Biosciences EPS beats by $0.06
  • seekingalpha.11/13 02:14

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About CALA

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
More

Webull offers Calithera Biosciences Inc (CALA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.